Swedish Orphan Biovitrum AB

SOBI

SE0000872095

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-06-28 EDT			5-day change	1st Jan Change
283.6 ^SEK	-0.21%		+2.60%	+6.22%

06-19	Sobi Wins EU Approval for Hemophilia A Drug Altuvoct	MT
06-19	European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A	CI

Swedish Orphan Biovitrum AB Provides Revenue Guidance for the Full Year 2021

May 04, 2021 at 12:00 am

Swedish Orphan Biovitrum AB (publ) provided revenue guidance for the full year 2021. Revenue for the full-year 2021 is expected to be in the range of SEK 14,000 million to SEK 15,000 million reported a year ago.

Latest news about Swedish Orphan Biovitrum AB

Sobi Wins EU Approval for Hemophilia A Drug Altuvoct	06-19	MT
European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A	06-19	CI
BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB	05-28	CI
Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment	05-24	DJ
Swedish Orphan Biovitrum AB Elects Zlatko Rihter as New Board Member	05-14	CI
Sobi Finalizes Inaugural SEK3 Billion Bond Issue	05-08	MT
Sobi Secures Additional EU Indication for Rare Blood Disorder Therapy	05-08	MT
Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug	04-26	MT
Sobi Receives Positive CHMP Opinion Recommending Approval of efanesoctocog alfa for Once-Weekly Treatment of Haemophilia A	04-26	CI
Sobi's SEK10 Billion Note Program Gets Regulatory Nod in Sweden	04-26	MT
Transcript : Swedish Orphan Biovitrum AB, Q1 2024 Earnings Call, Apr 25, 2024	04-25
Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Swedish Orphan Biovitrum AB Provides Earnings Guidance for 2024	04-25	CI
Certain Shares of Swedish Orphan Biovitrum AB are subject to a Lock-Up Agreement Ending on 14-MAR-2024.	03-13	CI
Sobi to Expand in South Korea via Rare Disease JV with Handok	02-13	MT
US Futures, European Stocks Mixed	02-12	DJ
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination	02-12	MT
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox	02-12	CI
Sobi's Growth Potential Remains 'Tremendous' Amid Conservative FY24 Outlook, RBC Says	02-09	MT
Transcript : Swedish Orphan Biovitrum AB, Q4 2023 Earnings Call, Feb 08, 2024	02-08
Swedish Orphan Biovitrum AB Provides Revenue Guidance for the Year 2024	02-08	CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-08	CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-08	CI
Sobi's Profit to Get Royalty Boost as Sanofi Partnerships Outperform, RBC Says	02-02	MT
Ericsson: new CFO in early April	01-23	CF

Chart Swedish Orphan Biovitrum AB

Duration

Period

More charts

Company Profile

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Companyâs product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.

Sector

Pharmaceuticals

Calendar

2024-07-15 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Ratings for Swedish Orphan Biovitrum AB

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

283.6 SEK

Average target price

329.6 SEK

Spread / Average Target

+16.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SWEDISH ORPHAN BIOVITRUM AB	+6.22%	9.09B
CSL LIMITED	+2.99%	95.18B
SAMSUNG BIOLOGICS CO.,LTD.	-4.34%	37.55B
UCB	+75.79%	28.2B
BIOMARIN PHARMACEUTICAL INC.	-14.61%	15.63B
INCYTE CORPORATION	-3.46%	13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.31%	11.5B
ALTEOGEN INC.	+184.77%	10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.13%	9.23B
INNOVENT BIOLOGICS, INC.	-13.92%	7.67B

Biopharmaceuticals